Participated · Series D · Jun 2023

Flywheel offers an enterprise imaging platform that aggregates, curates, and analyzes medical imaging and video data at scale, helping customers streamline research workflows and prepare AI-ready datasets. During 2025 the company broadened its product suite with a video viewing and annotation tool and launched Flywheel Validated, which supports 21 CFR Part 11–compliant imaging workflows for clinical trials. Its customer roster now includes 10 of the top 20 global pharmaceutical companies and 10 of the top 20 academic medical centers. Commercial traction was strong, with 43 % year-over-year growth in new business, a 40 % increase in committed revenue, and annual recurring revenue from pharma and device customers up 106 %. Net revenue retention exceeded 110 %, underscoring sticky usage and expansion within existing accounts. Backers of the company include Novalis LifeSciences, 8VC, NVIDIA, Microsoft, Novartis, and Intuitive Surgical. The new capital will be used to accelerate product innovation and further penetrate the clinical trial and AI model development markets.

Participated · Series B · Aug 2022

Digital Diagnostics is an AI diagnostics company focused on applying autonomous artificial intelligence to medical diagnosis. Its flagship product, IDx-DR, is an FDA De Novo cleared autonomous AI diagnostic system designed to detect diabetic retinopathy, including diabetic macular edema, at the point-of-care. The company raised $75M in a Series B round led by KKR. Proceeds will be used to accelerate the product roadmap, expand the company’s distribution footprint, and invest in sales and marketing. Leadership includes CEO John Bertrand, co-founder/president/COO Seth Rainford, and founder/executive chairman Dr. Michael D. Abramoff. The company is based in Coralville, Iowa and states its mission is to improve the quality, accessibility, equity, and affordability of global health care through technology. IDx develops clinically-aligned autonomous AI diagnostic algorithms that identify disease from medical images, and has an FDA-cleared system to detect diabetic retinopathy without clinician interpretation. The company's IDx-DR enables health care providers who are not normally involved in eye care to test for diabetic retinopathy during routine office visits. In June the solution was initiated into clinical practice at University of Iowa Health Care, marking the first time patients have received a medical diagnosis from an autonomous AI system in the United States. The company is working on implementations at several additional healthcare systems that plan to go live with IDx-DR in 2018. IDx is developing additional AI-based diagnostic systems for macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease and stroke risk. It intends to use the newly raised funds to accelerate market adoption and further develop additional diagnostic systems for its AI platform.